Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) a...
VLA1553 is currently the first and only chikungunya vaccine candidate worldwide for which regulatory review processes are underway. A Biologic License Appl...
ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-s...
Trial expected to screen more than 1900 early-stage breast cancer patients at 120+ sites in 12 countries across Europe, commencing in...
ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on dr...
Buzzreach is engaged in the development of a clinical trial and clinical research platform business that leverages the power of technology to address the c...
LG Chem announces initiation of two phase 2 clinical trials in patients with defects in MC4R pathway causing severe obesity and hyperphagia. - LG Chem cont...
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-source...
IPF is a chronic, progressive fibrosing interstitial pneumonia and one of the most fatal interstitial pneumonias. The incidence of IPF is high, but due to ...
Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population Phase ...
The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interi...
Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions, announced high-level results from NICE-01, the first-in-h...
© 2025 Biopharma Boardroom. All Rights Reserved.
